The Novo Nordisk Way is our values-based management system integrated into our corporate governance.
Doing business in a responsible way is the basis for long-term viability growth and profitability of a company.
At Novo Nordisk, we manage our business in a way that delivers competitive financial returns for shareholders through ethical business conduct and transparent business practices while contributing to socio-economic development.
Corporate Governance refers to the way a company is directed and controlled. Our values are consistent with the principles of good governance. Please click the below links to read more about how we work:
Our B shares are listed on Nasdaq Copenhagen and on the New York Stock Exchange as American Depository Receipts (ADRs). Please refer to the table below.
|Stock exchange||Listing type||Stock name|
|Copenhagen||Listed shares||DK0060534915 (ISIN)|
On the following pages, you can read more about our shares such as share capital and dividend payments. To search and download share price data for a specific date or date range, please use the ‘shareholder tools’.
Our tax approach is to pursue a competitive tax level in a responsible way. This means paying pay tax in jurisdictions where business activity generates profits.
‘Competitive tax level’ implies achieving a tax level around the peer-group average. ‘Responsible way’ implies doing business in a way that meets expectations of a good corporate citizen. This means paying taxes where profits are earned in accordance with international transfer pricing rules, having a balanced tax risk profile and not engaging in tax-avoidance activities. Therefore, a well-established subsidiary of Novo Nordisk will, in general, pay taxes in the country in which it operates.
We balance growth in the short term with long-term investments. This includes tackling unmet medical needs through research and development (R&D), tailoring production and distribution facilities, and building local healthcare capacity.
An example is our recent collaboration with the University of Oxford on a type 2 diabetes research centre. We will invest GBP 115m over a period of 10 years. For more information, click here.
Novo Nordisk uses long-term financial targets to drive the business towards long-term sustainable growth. These targets help our Executive Management balance growth in the short term with investments in longer-term growth, such as new production facilities and research and development activities.